China Biopharmaceuticals announced on the Hong Kong Stock Exchange that the medical imaging product Iodopromide injection (trade name: polyiodine) developed by the Group has obtained marketing approval from the China National Drug Administration. As a diagnostic drug, it can be used for intravascular and intra-body imaging.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.